127 related articles for article (PubMed ID: 38634966)
1. Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022.
Littlejohn G; Anbumurali N; O'Sullivan C; Smith T; Tymms K; Bird P; Nicholls D; Griffiths H
Clin Rheumatol; 2024 Jun; 43(6):1823-1832. PubMed ID: 38634966
[TBL] [Abstract][Full Text] [Related]
2. Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study.
Littlejohn G; Roberts L; Bird P; de Jager J; Griffiths H; Nicholls D; Young J; Zochling J; Tymms KE
J Rheumatol; 2015 Sep; 42(9):1603-9. PubMed ID: 26136482
[TBL] [Abstract][Full Text] [Related]
3. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.
Tymms K; Zochling J; Scott J; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Roberts L; Arnold M; Littlejohn G
Arthritis Care Res (Hoboken); 2014 Feb; 66(2):190-6. PubMed ID: 23983001
[TBL] [Abstract][Full Text] [Related]
4. A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control.
Littlejohn G; Roberts L; Arnold M; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Scott J; Zochling J; Tymms KE
Int J Rheum Dis; 2013 Oct; 16(5):532-8. PubMed ID: 24164840
[TBL] [Abstract][Full Text] [Related]
5. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
[TBL] [Abstract][Full Text] [Related]
6. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
[TBL] [Abstract][Full Text] [Related]
7. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
[TBL] [Abstract][Full Text] [Related]
9. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Remission and Low Disease Activity in Rheumatoid Arthritis Patients: Results From the Follow-up of a Real-World Peruvian Cohort.
Gamboa-Cárdenas RV; Ugarte-Gil MF; Pimentel-Quiroz V; Reátegui-Sokolova C; Rodríguez-Bellido Z; Zevallos-Miranda F; Medina-Chinchón M; Alfaro-Lozano J; Noriega-Zapata E; Cucho-Venegas JM; Perich-Campos R; Pastor-Asurza C; Alarcón GS
J Clin Rheumatol; 2022 Dec; 28(8):390-396. PubMed ID: 35697014
[TBL] [Abstract][Full Text] [Related]
11. Burden of disease and real-world treatment patterns of patients with systemic lupus erythematosus in the Australian OPAL dataset.
Ciciriello S; Littlejohn G; O'Sullivan C; Smith T; Deakin CT
Clin Rheumatol; 2023 Nov; 42(11):2971-2980. PubMed ID: 37407907
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
Lopez-Romero P; de la Torre I; Haladyj E; Aletaha D; Smolen JS
Ann Rheum Dis; 2022 May; 81(5):622-631. PubMed ID: 35193872
[TBL] [Abstract][Full Text] [Related]
13. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
[TBL] [Abstract][Full Text] [Related]
14. Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia.
Bird P; Littlejohn G; Butcher B; Smith T; da Fonseca Pereira C; Witcombe D; Griffiths H
Clin Rheumatol; 2020 Sep; 39(9):2545-2551. PubMed ID: 32157469
[TBL] [Abstract][Full Text] [Related]
15. Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset.
Youssef P; Marcal B; Button P; Truman M; Bird P; Griffiths H; Roberts L; Tymms K; Littlejohn G
J Rheumatol; 2020 Aug; 47(8):1174-1181. PubMed ID: 31787605
[TBL] [Abstract][Full Text] [Related]
16. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.
Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H
Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
20. Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study.
Zhu H; Li R; Da Z; Bi L; Li X; Li Y; Liu C; Zhang F; Li Z; Liu X; Zhang Z; Sun L; Wang Y; Zhang W; Jiang Q; Chen J; Chen Q; Li Z; Wu L; Qi W; Xu J; Cui X; Wang X; Li L; Leng X; Wang G; Zhao D; Jiang L; He D; Liu X; Li L; Fang Y; Huang C; Wu H; Hu S; Li Q; Song H; Xiao W; Gong L; Zhang L; Li X; Li Z; Su Y
Clin Rheumatol; 2018 Mar; 37(3):597-605. PubMed ID: 29116543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]